This company has been acquired
Salud financiera de hoja de balance de DICE Therapeutics
Salud financiera controles de criterios 6/6
DICE Therapeutics has a total shareholder equity of $519.1M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $550.7M and $31.6M respectively.
Información clave
0%
Ratio deuda-patrimonio
US$0
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | US$528.38m |
| Patrimonio | US$519.06m |
| Total pasivo | US$31.62m |
| Activos totales | US$550.67m |
Actualizaciones recientes sobre salud financiera
We're Not Very Worried About DICE Therapeutics' (NASDAQ:DICE) Cash Burn Rate
May 14
Here's Why We're Not Too Worried About DICE Therapeutics' (NASDAQ:DICE) Cash Burn Situation
Sep 11Recent updates
We're Not Very Worried About DICE Therapeutics' (NASDAQ:DICE) Cash Burn Rate
May 14DICE Therapeutics positive phase 1 data for psoriasis candidate leads shares 71% higher
Oct 11Here's Why We're Not Too Worried About DICE Therapeutics' (NASDAQ:DICE) Cash Burn Situation
Sep 11DICE Therapeutics GAAP EPS of -$0.58
Aug 11DICE Therapeutics initiated at buy at Wainwright on platform for small molecule drugs
Jul 18Análisis de la situación financiera
Pasivos a corto plazo: DICE's short term assets ($532.3M) exceed its short term liabilities ($20.6M).
Pasivo a largo plazo: DICE's short term assets ($532.3M) exceed its long term liabilities ($11.0M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: DICE is debt free.
Reducción de la deuda: DICE had no debt 5 years ago.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: DICE has sufficient cash runway for more than 3 years based on its current free cash flow.
Pronóstico de cash runway: DICE has sufficient cash runway for 2.9 years if free cash flow continues to reduce at historical rates of 46.7% each year.